An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

By E. Reinhold-Keller, Nadja Beuge, U. Latza, K. D. Groot, H. Rudert, Bernhard Nölle, Martin Heller, W. Gross. Arthritis & Rheumatism, 2000

737 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis (2009, background): “4 (1) 8 (3) 5 (2) 9 (4) 5 (2) 9 (4) 5 (2) 9 (4) 2 (1) 1 (1) 2 (1) 1 (1) 2 (1) 1 (1) 2 (1) 1 (1) 7 (4) 6 (2) 7 (4) 8 (4) 7 (4) 9 (5) 7 (4) 9 (5)”
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, background): “26 MESNA also retards the degradation of 4-hydroxymetabolites, further reducing the toxic acrolein products in the urine.”
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. (2005, background): “5 (22–78) 53 (18–78) Female/male 25/24 (51/49) 26/20 (57/43) 51/44 (54/46) WG 46 (94) 43 (93) 89 (94) MPA 3 (6) 3 (7) 6 (6) cANCA 41 (84) 35 (76) 76 (80) pANCA 4 (8) 6 (13) 10 (11) PR3 ANCA positive 37 (76) 33 (72) 70 (74) MPO ANCA positive 5 (11) 7 (15) 12 (13) Histologic confirmation of WG/MPA 30 ”
EULAR recommendations for the management of primary small and medium vessel vasculitis (2008, background): “Methotrexate (20–25 mg/week, oral or parenteral) can be used as an alternative to cyclophosphamide in patients with less severe disease and in whom renal function is normal.(13) 33 36 53–58 It”